Abera Bioscience

Executive Summary

Abera Bioscience is a Swedish biotechnology company developing next-generation mucosal vaccines using its proprietary Outer Membrane Vesicle (OMV) platform. The company's nasal spray vaccine candidates are designed to induce robust mucosal and systemic immunity, offering potential advantages in blocking transmission and ease of administration. Abera is currently in Phase 1 clinical development, focusing on cost-effective vaccines for seasonal and emerging pathogens. The company was founded in 2015 and is headquartered in Stockholm. As a private, early-stage biotech, Abera's progress is closely tied to its clinical trial results and platform validation. Key upcoming catalysts include initial Phase 1 safety and immunogenicity data from its lead vaccine candidate, which could demonstrate the platform's potential. The company may also pursue strategic partnerships for co-development or manufacturing, and could seek additional funding to advance its pipeline. While still pre-revenue, Abera's OMV technology has the potential to address significant unmet needs in mucosal vaccination.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Safety and Immunogenicity Data Readout60% success
• Q1 2027Partnership or Licensing Agreement for OMV Platform40% success
• Q2 2027Series A or B Financing Round70% success